Betterlife Pharma Stock Price To Earnings To Growth
| BETRF Stock | USD 0.07 0.01 14.62% |
BetterLife Pharma fundamentals help investors to digest information that contributes to BetterLife Pharma's financial success or failures. It also enables traders to predict the movement of BetterLife OTC Stock. The fundamental analysis module provides a way to measure BetterLife Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BetterLife Pharma otc stock.
BetterLife |
BetterLife Pharma OTC Stock Price To Earnings To Growth Analysis
BetterLife Pharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, BetterLife Pharma has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
BetterLife Fundamentals
| Return On Equity | -44.17 | |||
| Return On Asset | -4.05 | |||
| Current Valuation | 12.42 M | |||
| Shares Outstanding | 90.1 M | |||
| Shares Owned By Insiders | 8.41 % | |||
| Price To Book | 13.65 X | |||
| Gross Profit | (22.81 K) | |||
| EBITDA | (11.92 M) | |||
| Net Income | (12.16 M) | |||
| Cash And Equivalents | 14.41 K | |||
| Total Debt | 34.56 K | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (11.2 M) | |||
| Earnings Per Share | (0.12) X | |||
| Beta | 1.62 | |||
| Market Capitalization | 9.49 M | |||
| Total Asset | 1.16 M | |||
| Net Asset | 1.16 M |
About BetterLife Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BetterLife Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BetterLife Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BetterLife Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BetterLife OTC Stock
BetterLife Pharma financial ratios help investors to determine whether BetterLife OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BetterLife with respect to the benefits of owning BetterLife Pharma security.